Cargando…

Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study

BACKGROUND: In cancer patients with limited life expectancy, an implant of an intrathecal (IT) drug delivery system connected to a subcutaneous port (IDDS-SP) has been proposed as a successful strategy, but conflicting results are reported on quality of life (QoL). The aim of this prospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Giglio, Mariateresa, Preziosa, Angela, Mele, Roberta, Brienza, Nicola, Grasso, Salvatore, Puntillo, Filomena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607974/
https://www.ncbi.nlm.nih.gov/pubmed/36281899
http://dx.doi.org/10.1177/10732748221133752
_version_ 1784818672996450304
author Giglio, Mariateresa
Preziosa, Angela
Mele, Roberta
Brienza, Nicola
Grasso, Salvatore
Puntillo, Filomena
author_facet Giglio, Mariateresa
Preziosa, Angela
Mele, Roberta
Brienza, Nicola
Grasso, Salvatore
Puntillo, Filomena
author_sort Giglio, Mariateresa
collection PubMed
description BACKGROUND: In cancer patients with limited life expectancy, an implant of an intrathecal (IT) drug delivery system connected to a subcutaneous port (IDDS-SP) has been proposed as a successful strategy, but conflicting results are reported on quality of life (QoL). The aim of this prospective observational study is to report the effects on pain, mood and QoL of an IT combination therapy delivered by an IDDS-SP in malignant refractory pain. METHODS: Adult patients in which IT therapy was recommended were recruited. An IT therapy with morphine and levobupivacaine was started: VASPI score, depression and anxiety (evaluated by the Edmonton Symptom Assessment System -ESAS-), the Pittsburgh Sleep Quality Index (PSQI), the 5-level EuroQol 5D version (EQ-5D-5L) and the requirements of breakthrough cancer pain (BTcP) medications were registered, with adverse events rate and the satisfaction of patients scored as Patient Global Impression of Change (PGIC). RESULTS: Fifty patients, (16 F/34 M) were enrolled (age 69 ± 12). All had advanced cancer with metastasis. The median daily VASPI score was 75, the median depression score was 6, and the median anxiety score was 4, median PSQI was 16. At 28 days, a significant reduction in VASPI score was registered as well as in depression and anxiety item. Also, PSQI decreased significantly. The EQ-5D-5 L showed a significant improvement in all components at 14 and 28 days. Patient Global Impression of Change scores showed high level of satisfaction. A low incidence of adverse events and a reduction in BTCP episodes were also registered. CONCLUSION: Intrathecal combination therapy delivered by an IDDS-SP could ensure adequate control of cancer related symptoms, such as pain, depression, anxiety and sleep disturbances. These effects, with low rate of AEs and reduced BTcP episodes, could explain the improvement in QoL and the overall high levels of patients’ satisfaction.
format Online
Article
Text
id pubmed-9607974
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96079742022-10-28 Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study Giglio, Mariateresa Preziosa, Angela Mele, Roberta Brienza, Nicola Grasso, Salvatore Puntillo, Filomena Cancer Control Original Research Article BACKGROUND: In cancer patients with limited life expectancy, an implant of an intrathecal (IT) drug delivery system connected to a subcutaneous port (IDDS-SP) has been proposed as a successful strategy, but conflicting results are reported on quality of life (QoL). The aim of this prospective observational study is to report the effects on pain, mood and QoL of an IT combination therapy delivered by an IDDS-SP in malignant refractory pain. METHODS: Adult patients in which IT therapy was recommended were recruited. An IT therapy with morphine and levobupivacaine was started: VASPI score, depression and anxiety (evaluated by the Edmonton Symptom Assessment System -ESAS-), the Pittsburgh Sleep Quality Index (PSQI), the 5-level EuroQol 5D version (EQ-5D-5L) and the requirements of breakthrough cancer pain (BTcP) medications were registered, with adverse events rate and the satisfaction of patients scored as Patient Global Impression of Change (PGIC). RESULTS: Fifty patients, (16 F/34 M) were enrolled (age 69 ± 12). All had advanced cancer with metastasis. The median daily VASPI score was 75, the median depression score was 6, and the median anxiety score was 4, median PSQI was 16. At 28 days, a significant reduction in VASPI score was registered as well as in depression and anxiety item. Also, PSQI decreased significantly. The EQ-5D-5 L showed a significant improvement in all components at 14 and 28 days. Patient Global Impression of Change scores showed high level of satisfaction. A low incidence of adverse events and a reduction in BTCP episodes were also registered. CONCLUSION: Intrathecal combination therapy delivered by an IDDS-SP could ensure adequate control of cancer related symptoms, such as pain, depression, anxiety and sleep disturbances. These effects, with low rate of AEs and reduced BTcP episodes, could explain the improvement in QoL and the overall high levels of patients’ satisfaction. SAGE Publications 2022-10-25 /pmc/articles/PMC9607974/ /pubmed/36281899 http://dx.doi.org/10.1177/10732748221133752 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Giglio, Mariateresa
Preziosa, Angela
Mele, Roberta
Brienza, Nicola
Grasso, Salvatore
Puntillo, Filomena
Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title_full Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title_fullStr Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title_full_unstemmed Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title_short Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study
title_sort effects of an intrathecal drug delivery system connected to a subcutaneous port on pain, mood and quality of life in end stage cancer patients: an observational study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607974/
https://www.ncbi.nlm.nih.gov/pubmed/36281899
http://dx.doi.org/10.1177/10732748221133752
work_keys_str_mv AT gigliomariateresa effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy
AT preziosaangela effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy
AT meleroberta effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy
AT brienzanicola effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy
AT grassosalvatore effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy
AT puntillofilomena effectsofanintrathecaldrugdeliverysystemconnectedtoasubcutaneousportonpainmoodandqualityoflifeinendstagecancerpatientsanobservationalstudy